Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection-Reference-Cited by-同舟云学术

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Published:2019-12-26 Issue:5 Volume:40 Page:1032-1041
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Lawitz Eric¹,Flisiak Robert²^ORCID,Abunimeh Manal³,Sise Meghan E.⁴,Park Jun Y.⁵^ORCID,Kaskas Marwan⁶,Bruchfeld Annette⁷,Wörns Marcus‐Alexander⁸,Aglitti Andrea⁹,Zamor Philippe J.¹⁰,Xue Zhenyi³,Schnell Gretja³,Jalundhwala Yash J.³,Porcalla Ariel³,Mensa Federico J.³,Persico Marcello⁹^ORCID

Affiliation:

1. The Texas Liver Institute University of Texas Health San Antonio San Antonio TX USA

2. Department of Infectious Diseases and Hepatology Medical University of Bialystok Bialystok Poland

3. AbbVie, Inc. North Chicago IL USA

4. Department of Medicine Division of Nephrology Massachusetts General Hospital Boston MA USA

5. Department of Internal Medicine Yonsei University College of Medicine Seoul South Korea

6. Northwest Louisiana Nephrology Shreveport LA USA

7. Department of Renal Medicine Karolinska University Hospital Karolinska Institutet Stockholm Sweden

8. Department of Internal Medicine University Medical Center of the Johannes Gutenberg‐University Mainz Mainz Germany

9. Internal Medicine and Hepatology Unit University of Salerno Salerno Italy

10. Carolinas Medical Center Charlotte NC USA

Funder

AbbVie

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14320

Reference42 articles.

1. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal

2. A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C

3. Extrahepatic manifestations of chronic hepatitis C virus infection

4. HCV syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer

5. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review;Expert Opinion on Pharmacotherapy;2024-08-12

2. The Fixed Dose Combination of Sofosbuvir and Velpatasvir is Safe and Effective in Patients of Chronic Hepatitis C With End-stage Renal Disease;Journal of Clinical and Experimental Hepatology;2024-07

3. Identifying Gaps in the Treatment Guidelines for Hepatitis C in Peru to Meet International Standards: A Narrative Review;Journal of Clinical Medicine;2024-06-30

4. Efficacy of Sofosbuvir and Velpatasvir Combination in the Treatment of Hepatitis C Virus (HCV) in Chronic Kidney Disease (CKD) Patients;Cureus;2024-05-22

5. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals;Expert Opinion on Pharmacotherapy;2024-05-02